Skip to content

Study · In vitro (cells) · 2010

8 results

Actin-sequestering protein, thymosin beta-4, induces paclitaxel resistance through ROS/HIF-1alpha stabilization in HeLa human cervical tumor cells.

Oh JM, Moon EY

Life sciences14 Jul 2010Cited by 21 (Europe PMC)

PMID20637781 (opens in a new tab)DOI10.1016/j.lfs.2010.07.002 (opens in a new tab)PepBankPUB-20637781
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In HeLa human cervical tumor cells, thymosin beta‑4 protein increased intracellular reactive oxygen species.

    In plain wordsIn cells, thymosin beta‑4 protein raised the level of reactive oxygen species in cervical tumor cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIntracellular ROS level
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Oxidative stress · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4 protein (TB4P) significantly increased intracellular ROS level
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.
  2. 02LabIn vitro (cells)Mechanism

    In HeLa human cervical tumor cells, thymosin beta‑4 protein increased HIF-1alpha.

    In plain wordsIn cells, thymosin beta‑4 protein raised HIF-1alpha in cervical tumor cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHIF-1alpha level
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4 protein (TB4P) significantly increased intracellular ROS level and HIF-1alpha.
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.
  3. 03LabIn vitro (cells)Mechanism

    In HeLa human cervical tumor cells, thymosin beta‑4 protein activated nuclear factor kappa B.

    In plain wordsIn cells, thymosin beta‑4 protein activated nuclear factor kappa B in cervical tumor cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseNF-kappaB activation
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    TB4P-induced ROS production was confirmed by the activation of nuclear factor kappa B.
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.

Studies that did not test the peptide alone5

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In TB4-transgenic mice, paclitaxel-induced B16F10 melanoma regression was inhibited compared with wildtype mice.

    In plain wordsIn mice bred to make extra thymosin beta‑4, a cancer drug shrank melanoma less than in normal mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreasePaclitaxel-induced melanoma regression
    Study

    mousen: not reported in source

    TB4-transgenic mice with B16F10 melanoma
    Comparator
    Wildtype mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Paclitaxel-induced B16F10 mouse melanoma regression was physiologically inhibited in TB4-transgenic mice compared to wildtype mice.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome

    In HeLa human cervical tumor cells, thymosin beta‑4 gene overexpression and thymosin beta‑4 protein treatment decreased tumor cell death.

    In plain wordsIn HeLa cervical tumor cells, raising Tβ4 gene activity, or adding Tβ4 protein, lowered tumor cell death.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTumor cell death
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In addition, tumor cell death was decreased by TB4 gene overexpression and TB4P treatment.
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In HeLa cells, the ROS scavenger N-acetylcysteine reduced the HIF-1alpha level that thymosin beta‑4 protein had raised.

    In plain wordsIn cells, a ROS scavenger lowered the HIF-1alpha rise that thymosin beta‑4 protein caused.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseHIF-1alpha level with N-acetylcysteine
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    The increased level of HIF-1alpha by TB4P was reduced by the treatment with N-acetylcysteine (NAC), a well-known ROS scavenger.
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In HeLa cells, N-acetylcysteine attenuated the Erk phosphorylation that thymosin beta‑4 protein had induced.

    In plain wordsIn cells, a ROS scavenger weakened the Erk phosphorylation that thymosin beta‑4 protein caused.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseErk phosphorylation with N-acetylcysteine
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    TB4P-induced Erk phosphorylation was attenuated by the treatment with NAC.
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 08LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome

    In HeLa cells, N-acetylcysteine attenuated the tumor cell density that thymosin beta‑4 protein had increased.

    In plain wordsIn cells, a ROS scavenger lowered the tumor cell density that thymosin beta‑4 protein had raised.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTumor cell density with N-acetylcysteine
    Study

    humann: not reported in source

    HeLa human cervical tumor cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    NAC treatment attenuated tumor cell density increased by TB4P.
    1 context sentence
    Summary · context
    HeLa human cervical tumor cells were used.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.